PMID- 37799353
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231026
IS  - 2690-442X (Electronic)
IS  - 2690-442X (Linking)
VI  - 3
IP  - 5
DP  - 2023 Oct
TI  - Tolerance of sonidegib after intolerance of vismodegib-Experience in two patients 
      with nevoid basal cell carcinoma syndrome (Gorlin syndrome).
PG  - e260
LID - 10.1002/ski2.260 [doi]
LID - e260
AB  - Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic 
      condition characterized by the early development of numerous cutaneous basal cell 
      carcinomas (BCCs). Although most BCCs are surgically treated with total 
      resection, some of the lesions may proceed to a locally advanced or metastatic 
      stage. Systemic treatment with a hedgehog inhibitors (HHIs) such as Vismodegib or 
      Sonidegib is indicated in this population. We report cases of two patients with 
      confirmed diagnoses of NBCCS. Both patients had undergone multiple surgical 
      excisions and had been treated with oral Vismodegib 150 mg/day for a locally 
      advanced tumour. They both discontinued the therapy due to its specific adverse 
      effects (AEs) and are now being treated with oral Sonidegib, which has had better 
      tolerability and a complete response. The aims of this report was to demonstrate 
      the efficacy of HHI treatment with Sonidegib in patients with NCBBS who had 
      previously treated with Vismodegib but discontinued it because of its specific 
      AEs. Our experience in two patients shows that Sonidegib can be considered in 
      Gorlin patients intolerant but responding to Vismodegib.
CI  - (c) 2023 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on 
      behalf of British Association of Dermatologists.
FAU - Venturi, Federico
AU  - Venturi F
AUID- ORCID: 0000-0001-5053-4172
AD  - Section of Dermatology Department of Health Sciences University of Florence 
      Florence Italy.
AD  - IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy.
AD  - Dermatology Unit, Department of Medical and Surgical Sciences (DIMEC), Alma Mater 
      Studiorum University of Bologna Bologna Italy.
FAU - Trane, Luciana
AU  - Trane L
AD  - Cancer Research "Attilia Pofferi" Foundation Pistoia Italy.
FAU - Silvestri, Flavia
AU  - Silvestri F
AD  - Section of Dermatology Department of Health Sciences University of Florence 
      Florence Italy.
FAU - Zuccaro, Biancamaria
AU  - Zuccaro B
AD  - Section of Dermatology Department of Health Sciences University of Florence 
      Florence Italy.
FAU - Magnaterra, Elisabetta
AU  - Magnaterra E
AD  - Section of Dermatology Department of Health Sciences University of Florence 
      Florence Italy.
FAU - De Giorgi, Vincenzo
AU  - De Giorgi V
AUID- ORCID: 0000-0001-6531-7998
AD  - Section of Dermatology Department of Health Sciences University of Florence 
      Florence Italy.
LA  - eng
PT  - Case Reports
DEP - 20230614
PL  - England
TA  - Skin Health Dis
JT  - Skin health and disease
JID - 9918227353706676
PMC - PMC10549827
COIS- The authors declared that they have no conflicts of interest to this work.
EDAT- 2023/10/06 06:43
MHDA- 2023/10/06 06:44
PMCR- 2023/06/14
CRDT- 2023/10/06 03:48
PHST- 2023/04/30 00:00 [received]
PHST- 2023/05/29 00:00 [revised]
PHST- 2023/06/01 00:00 [accepted]
PHST- 2023/10/06 06:44 [medline]
PHST- 2023/10/06 06:43 [pubmed]
PHST- 2023/10/06 03:48 [entrez]
PHST- 2023/06/14 00:00 [pmc-release]
AID - SKI2260 [pii]
AID - 10.1002/ski2.260 [doi]
PST - epublish
SO  - Skin Health Dis. 2023 Jun 14;3(5):e260. doi: 10.1002/ski2.260. eCollection 2023 
      Oct.